Title Segment Summary Type Price Published

Drug Delivery Market Pharmaceutical The global drug delivery market has grown from an Market 3000 Euros January 2009
estimated $26bn in 2000 to approximately $60bn in 2006. Report
The market has witnessed rapid expansion due to patent
expiration of blockbuster drugs, stringent FDA regulations,
an increased focus on the expansion of products' life-cycle,
cost-effective production of neoteric delivery vehicles, and
the emergence of a range of delivery solutions and hybrid
platforms.

Durable Medical Healthcare Durable medical equipment (DME) is defined as instruments Market 1300 Euros September 2009
Equipment: U.S. Market and products used for medical purposes and that can Report
Size, Growth and Trends withstand repeated usage. DME is used primarily to help
improve the quality of life of patients with injuries or
illnesses.

Different stakeholders segment DME in different ways,

making the market more or less inclusive. For the purpose
of this report, we divided the DME market in six therapeutic
segments: Home respiratory therapy, Home
infusions, Diabetes supplies, Patient positioning, Patient
mobility, Other equipment.

Using this segmentation, we estimate that the U.S. DME

market reached ~$27B in 2009. We expect this market to
grow 6% per annum to $34B by 2013, with various
segments growing in the mid- to high- single-digits. We
review the factors that will be driving and moderating this
growth, such as patient satisfaction,outcome and cost.
DME products are distributed primarily by national and local
providers; other channels, such as 3rd party distributors or
mail-in orders exist for some channels.

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 1/6

Fluidigm Due Diligence: Life Science Fluidigm is a life science company that develops and Company 800 Euros September 2009
Company Profile, SWOT distributes instruments and chips for genomic analysis and Profile
Analysis and Market X-ray crystallography applications. The company owns a
Opportunity
disruptive and scalable integrated fluidic circuits (IFC)
technology.

This technology enables the execution of thousands of

experiments in parallel in nanoliter volumes, and facilitates
implementation of experiments with a complex design.

Since its inception in 1999, Fluidigm has incurred >$150M

in operating losses. While profitability in the next 1-2 years
is unlikely, Fluidigm has strong revenue potential given its
deep intellectual property portfolio and growth of its
targetmarkets.

Roflumilast (Daxas) Pharmaceutical Chronic obstructive pulmonary disease (COPD) remains a Product 1500 Euros November 2009
significant area of unmet medical need. It is a progressive Report
and irreversible lung disease that restricts breathing.

Daxas (Roflumilast) is a phosphodiesterase-4 (PDE4)

inhibitor that is being developed to treat the underlying
inflammation in COPD and related inflammatory diseases. It
could be both the first PDE4 inhibitor and the first orally
administered anti-inflammatory treatment for COPD
patients. As a once-daily, non-steroidal anti-inflammatory
treatment, Daxas� offers the opportunity for a new
approach to the treatment of COPD.

Systemic Lupus Pharmaceutical Lupus is one of many disorders of the immune system Market 4000 Euros November 2009
Erythematosus (SLE) known as autoimmune diseases. In autoimmune diseases, Report
the immune system turns against parts of the body it is
designed to protect.
This leads to inflammation and damage to various body
tissues. Lupus can affect many parts of the body, including

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 2/6

 the joints, skin, kidneys, heart, lungs, blood vessels, and
brain. Although people with the disease may have many
different symptoms, some of the most common ones
include extreme fatigue, painful or swollen joints (arthritis),
unexplained fever, skin rashes, and kidney problems.

Wegener's Granulomatosis Pharmaceutical Wegener's granulomatosis is a necrotizing granulomatous Disease 1500 Euros November 2009
(WG) vasculitis with the prevalence of 3 in 100 000. The disease Report
was first described in 1931 by a medical student in
Germany named Heinz Klinger. Afterwards, in 1936 Dr.
Wegener a young German pathologist gave a detailed
explanation regarding three patients suffering from this
disease.Although it is an uncommon disease, if not
diagnosed and treated in-time my cause renal failure and
severe pulmonary complications including diffuse pulmonary
hemorrhage. Therefore, timely diagnosis and treatment is
important in preventing related morbidity and mortality.
Pulmonary involvement is the most common form of the
disease manifested in 95% of cases but onset of the disease
with rare symptoms such as proptosis (in 2% of the cases)
and hyperthyroidism (in 1% of the cases) has been
reported as well.

Molecular Diagnostics: Diagnostics Molecular diagnostics (MDx) is the fastest growing segment Market 1500 Euros November 2009
Market Segmentation and of the in vitro diagnostics industry (IVD). With a market Report
Opportunities size of ~$4B in 2009, and a double digit growth rate, this
attractive segment continues to be a major contributor in
the evolution of the healthcare landscape.

MDx involves platforms and assays that leverage multiple

technologies to identify genetic variations in individual
patients. These technologies offer significant advantages
such as time-to-result and cost-effectiveness over culture-
based or immune-based techniques.

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 3/6

 This report reviews the market size, growth, segments and
trends of the MDx industry from 2006 to 2012. The market
is segmented to provide insights on specific growth
opportunities by therapeutic areas, analytes tested (i.e.,
plex level), test rationale, test location and geography.

Major competitors are reviewed along with their key

platforms. Competitors shaping the industry include
BioPharma (e.g., Abbott, Roche), IVD/MDx pure-play
companies (e.g., BioMerieux, Cepheid, Gen-probe) or
research tool companies (e.g., Illumina, Life Technologies).

Dry Eye Disease Pharmaceutical Dry eye disease (DED) is one of the most frequently Disease 6000 Euros December 2009
encountered ocular morbidities. 25 % percent of patients Report
who visit ophthalmic clinics report symptoms of dry eye,
making it a growing public health problem and one of the
most common conditions seen by eye care practitioners.
Historically, the term "Keratoconjunctivitis sicca" can be
attributed to the Swedish ophthalmologist Henrik SC jögren.
He was the first to refer to the triad of Keratoconjunctivitis
sicca, dry mouth, and joint pain, which occurs mainly in
women (90% of the cases) (www.sjogrens.org), and in
1950 Andrew De Roetth introduced the term "dry eye". For
many decades, DED was thought to be limited to dryness of
the eyes due to reduction of the aqueous phase of the tear
film. In 1995, DED was defined as a complex multifaceted
group of medical and ocular diseases that is due to
decreased tear production and/or increased tear
evaporation. In 2007, the International Dry Eye Workshop
(DEWS) revised the original definition and classification
scheme of DED and developed a new definition, as well as a
three‐part classification of DED based on etiology,
mechanism, and severity of the disease.
See also: http://www.dry-eye-disease.com/

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 4/6

Qiagen: Company Profile Diagnostics Qiagen develops and markets biological sample preparation Company 700 Euros December 2009
and SWOT Analysis and analysis products for academic, biopharmaceutical and Profile
molecular diagnostics companies. These products are
considered standards by these customers.
Qiagen has experienced impressive double-digit revenue
growth over the last few years, in part driven by increased
exposure to MDx.
Over the last few years, Qiagen has started a transition
from life science research tools to molecular
diagnostic(MDx),triggered by the strategic acquisition of
Digene. This transaction reflects the increasing interest
research tools companies have for the attractive MDx
market, a ~$4B market that is experiencing double digit
growth.

Cepheid Swot Analysis Diagnostics Cepheid (NASDAQ: CPHD) is a leading nucleic acid (NA) Company 350 Euros February 2010
testing company based in Sunnyvale, CA. Founded in 1996, Profile
the company develops, manufactures, and markets fully-
integrated systems and tests for genetic analysis in the
clinical, industrial and biothreat markets.

Alzheimer Disease Pharmaceutical Alzheimer's disease (AD) is by far the most common cause Market 5000 Euros June 2010
of dementia associated with aging; it accounts for more Report
than 60% of all dementia. Alzheimer's disease is
characterized by an insidious onset and slow deterioration
in cognition, functional ability (e.g., activities of daily
living), behavior, and mood. In USA, AD is the 7th leading
cause of mortality.
In 2010, more of 21 million people will be affected by this
disease in the world. As the world population ages, this
number will increase.
See also www.disease-alzheimer.com

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 5/6

CBDM. T – Market and Business Intelligence

Main office:
75 rue de la Mare
Fr-75020 Paris, France
Tel: +33 1 4474 7957
Fax: +33 1 7711 8459
See also www.cbdmt.com
To contact Philippe Tramoy – Managing Partner

Israel:
POBox 6235
Netanya – 42490, Israel

Switzerland:
6, rte de Meyrin
1202 Geneva, Switzerland

CBDMT – Market & Business Intelligence © 2010 www.cbdmt.com 6/6